Literature DB >> 8555906

Guidelines for prescribing combined oral contraceptives.

A M Mills, C L Wilkinson, D R Bromham, J Elias, K Fotherby, J Guillebaud, A Kubba, A Wade.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8555906      PMCID： PMC2349741          DOI： 10.1136/bmj.312.7023.121a

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.

Authors:  K W Bloemenkamp; F R Rosendaal; F M Helmerhorst; H R Büller; J P Vandenbroucke
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

2.  Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

Authors:  H Jick; S S Jick; V Gurewich; M W Myers; C Vasilakis
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

3.  Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.

Authors:  W O Spitzer; M A Lewis; L A Heinemann; M Thorogood; K D MacRae
Journal:  BMJ       Date:  1996-01-13

4.  Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.

Authors:  M A Lewis; W O Spitzer; L A Heinemann; K D MacRae; R Bruppacher; M Thorogood
Journal:  BMJ       Date:  1996-01-13
  4 in total
  1 in total

1.  Diane-35 (cyproterone acetate): safety concerns.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2003-02-18       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.